RASL11A

Summary

RASL11A (RAS like family 11 member A, HGNC:23802) is a protein-coding gene on chromosome 13q12.2, encoding Ras-like protein family member 11A (Q6T310). Regulator of rDNA transcription.

Predicted to enable G protein activity and GTP binding activity. Predicted to be involved in positive regulation of transcription by RNA polymerase I. Predicted to be located in nucleolus.

Source: NCBI Gene 387496 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 37 total
• MANE Select transcript: NM_206827

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23802
Approved symbol	RASL11A
Name	RAS like family 11 member A
Location	13q12.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000122035
Ensembl biotype	protein_coding
OMIM	612403
Entrez	387496

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 3 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000241463, ENST00000475647, ENST00000480803, ENST00000882286, ENST00000967034

RefSeq mRNA: 2 — MANE Select: NM_206827 NM_001331126, NM_206827

CCDS: CCDS9321

Canonical transcript exons

ENST00000241463 — 4 exons

Exon	Start	End
ENSE00001157761	27273027	27275192
ENSE00001256962	27270830	27271068
ENSE00003468540	27271639	27271718
ENSE00003478054	27271484	27271540

Expression profiles

Bgee: expression breadth ubiquitous, 163 present calls, max score 97.14.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.0803 / max 234.1169, expressed in 1086 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
134516	4.5439	952
134515	0.5364	327

Top tissues by expression

254 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of stomach	UBERON:0001199	97.14	gold quality
right coronary artery	UBERON:0001625	95.08	gold quality
left coronary artery	UBERON:0001626	94.24	gold quality
rectum	UBERON:0001052	93.97	gold quality
mucosa of transverse colon	UBERON:0004991	92.97	gold quality
descending thoracic aorta	UBERON:0002345	92.81	gold quality
thoracic aorta	UBERON:0001515	91.85	gold quality
metanephros cortex	UBERON:0010533	91.46	gold quality
ascending aorta	UBERON:0001496	91.45	gold quality
coronary artery	UBERON:0001621	91.41	gold quality
popliteal artery	UBERON:0002250	91.39	gold quality
tibial artery	UBERON:0007610	91.38	gold quality
aorta	UBERON:0000947	91.29	gold quality
left uterine tube	UBERON:0001303	91.02	gold quality
oocyte	CL:0000023	90.59	gold quality
smooth muscle tissue	UBERON:0001135	89.96	gold quality
endocervix	UBERON:0000458	89.89	gold quality
omental fat pad	UBERON:0010414	89.63	gold quality
peritoneum	UBERON:0002358	89.50	gold quality
lower esophagus muscularis layer	UBERON:0035833	89.39	gold quality
right lung	UBERON:0002167	89.36	gold quality
lower esophagus	UBERON:0013473	89.35	gold quality
transverse colon	UBERON:0001157	88.99	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	88.52	gold quality
small intestine Peyer’s patch	UBERON:0003454	88.48	gold quality
body of uterus	UBERON:0009853	88.31	gold quality
ectocervix	UBERON:0012249	88.28	gold quality
gall bladder	UBERON:0002110	88.00	gold quality
muscle layer of sigmoid colon	UBERON:0035805	87.08	gold quality
adipose tissue of abdominal region	UBERON:0007808	86.99	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.50
E-GEOD-70580	no	3.21

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

7 targeting RASL11A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-1208	99.70	68.28	1533
HSA-MIR-4643	99.49	67.63	1791
HSA-MIR-146A-3P	99.13	68.99	1881
HSA-MIR-6818-5P	97.50	67.10	1167
HSA-MIR-4714-5P	97.04	67.76	955
HSA-MIR-5586-5P	96.29	68.02	685

Literature-anchored findings (GeneRIF, showing 3)

• RASL11A is down-regulated in prostate tumors as measured by quantitative real-time PCR. This result suggests that this gene may have a tumor suppressor role in prostate cancer. (PMID:15033445)
• In transient transfection experiments, RasL11a enhanced the transcriptional activity of an RNA polymerase I-specific reporter controlled by the rDNA enhancer/promoter region. (PMID:20168301)
• One gene, RASL11A, localized on chromosome band 13q12.2, escaped the copy number-induced overexpression and was reproducibly and significantly down-regulated on the mRNA and protein level (P=.0001, FDR=0.002). RASL11A expression levels were also lower in primary colorectal tumors as compared to matched normal mucosa (P=.0001, FDR=0.0001 (PMID:31174021)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Rasl11a	ENSMUSG00000029641
rattus_norvegicus	Rasl11a	ENSRNOG00000000956

Paralogs (35): RALA (ENSG00000006451), REM1 (ENSG00000088320), RASL10A (ENSG00000100276), RASD2 (ENSG00000100302), RASL12 (ENSG00000103710), RHEB (ENSG00000106615), RASD1 (ENSG00000108551), RERGL (ENSG00000111404), RAP1A (ENSG00000116473), RAP2C (ENSG00000123728), RAP2A (ENSG00000125249), RRAS (ENSG00000126458), RAP1B (ENSG00000127314), RASL11B (ENSG00000128045), KRAS (ENSG00000133703), RRAS2 (ENSG00000133818), RERG (ENSG00000134533), REM2 (ENSG00000139890), RIT1 (ENSG00000143622), RALB (ENSG00000144118), RIT2 (ENSG00000152214), MRAS (ENSG00000158186), DIRAS3 (ENSG00000162595), GEM (ENSG00000164949), DIRAS2 (ENSG00000165023), RRAD (ENSG00000166592), RHEBL1 (ENSG00000167550), NKIRAS2 (ENSG00000168256), HRAS (ENSG00000174775), DIRAS1 (ENSG00000176490), RAP2B (ENSG00000181467), ERAS (ENSG00000187682), NKIRAS1 (ENSG00000197885), NRAS (ENSG00000213281), RASL10B (ENSG00000270885)

Protein

Protein identifiers

Ras-like protein family member 11A — Q6T310 (reviewed: Q6T310)

All UniProt accessions (1): Q6T310

UniProt curated annotations — full annotation on UniProt →

Function. Regulator of rDNA transcription. Acts in cooperation UBF/UBTF and positively regulates RNA polymerase I transcription.

Subunit / interactions. Interacts with UBF/UBTF.

Subcellular location. Nucleus. Nucleolus.

Tissue specificity. Widely expressed. Down-regulated in prostate tumors compared to normal prostate tissue. High levels found in colon tumor and normal colon tissue followed by small intestine, liver, jejunum, ileum, bladder and aorta. Lowest levels observed in endothelial cells.

Induction. Down-regulated by TGFB1.

Similarity. Belongs to the small GTPase superfamily. Ras family.

RefSeq proteins (2): NP_001318055, NP_996563* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001806	Small_GTPase	Family
IPR005225	Small_GTP-bd	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR051065	Ras-related_GTPase	Family

Pfam: PF00071

Enzyme classification (BRENDA):

• EC 3.6.5.2 — small monomeric GTPase (BRENDA: 49 organisms, 138 substrates, 55 inhibitors, 5 Km, 1 kcat entries)

Substrate kinetics (BRENDA)

1 substrates with measured Km, best-characterized 1. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
GTP	—	0

Catalyzed reactions (Rhea), 1 shown:

• GTP + H2O = GDP + phosphate + H(+) (RHEA:19669)

UniProt features (5 total): binding site 3, chain 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6T310-F1	78.96	0.51

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 34–41; 81–85; 147–150

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 70 (showing top): GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_UP, WEBER_METHYLATED_IN_COLON_CANCER, CUI_TCF21_TARGETS_2_DN, GOCC_NUCLEOLUS, GOMF_GTPASE_ACTIVITY, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_ACID_ANHYDRIDES, NFAT_Q6, YOSHIMURA_MAPK8_TARGETS_UP, YOSHIMURA_MAPK8_TARGETS_DN, KARLSSON_TGFB1_TARGETS_DN, MARTENS_TRETINOIN_RESPONSE_DN, STAMBOLSKY_TARGETS_OF_MUTATED_TP53_UP, GOBP_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_I, GOBP_TRANSCRIPTION_BY_RNA_POLYMERASE_I, GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_I

GO Biological Process (1): positive regulation of transcription by RNA polymerase I (GO:0045943)

GO Molecular Function (6): G protein activity (GO:0003925), GTP binding (GO:0005525), nucleotide binding (GO:0000166), GTPase activity (GO:0003924), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (2): nucleolus (GO:0005730), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase I	1
transcription by RNA polymerase I	1
positive regulation of DNA-templated transcription	1
GTPase activity	1
molecular function regulator activity	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
ribonucleoside triphosphate phosphatase activity	1
binding	1
catalytic activity	1
nuclear lumen	1
intracellular membraneless organelle	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1269 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RASL11A	ARL9	Q6T311	916
RASL11A	ARL10	Q8N8L6	867
RASL11A	EIF1AD	Q8N9N8	471
RASL11A	RNF34	Q969K3	437
RASL11A	TGFB1	P01137	427
RASL11A	FAM78A	Q5JUQ0	386
RASL11A	CLPSL2	Q6UWE3	370
RASL11A	BTG4	Q9NY30	368
RASL11A	MAN1A1	P33908	366
RASL11A	GJD4	Q96KN9	365
RASL11A	ANKRD24	Q8TF21	357
RASL11A	KNCN	A6PVL3	348
RASL11A	LLGL1	Q15334	345
RASL11A	EIF1AX	P47813	334
RASL11A	PHYHIP	Q92561	333

IntAct

7 interactions, top by confidence:

A	B	Type	Score
HTT	RASL11A	psi-mi:“MI:0915”(physical association)	0.560
RASL11A	ARHGEF17	psi-mi:“MI:0915”(physical association)	0.500
	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
RASL11A	MBL2	psi-mi:“MI:0914”(association)	0.350

BioGRID (13): ARHGEF17 (Affinity Capture-MS), RTFDC1 (Affinity Capture-MS), SAR1B (Affinity Capture-MS), SBDS (Affinity Capture-MS), MBL2 (Affinity Capture-MS), PRPS1L1 (Affinity Capture-MS), TMOD1 (Affinity Capture-MS), TPK1 (Affinity Capture-MS), PKLR (Affinity Capture-MS), TIGIT (Affinity Capture-MS), DTYMK (Affinity Capture-MS), RASL11A (Affinity Capture-MS), RASL11A (Affinity Capture-RNA)

ESM2 similar proteins: A1DZY4, A6QP66, O35626, O35929, O88910, O88954, P0C0E4, P35295, P51157, P51158, P53667, P53668, P53669, P55040, P55041, P55043, P63032, P63033, Q06AU5, Q12829, Q13368, Q13637, Q3SWY9, Q5E9J3, Q5FVY2, Q5R541, Q5RFI2, Q6DGN0, Q6IMA3, Q6IMA7, Q6IMB1, Q6P0U3, Q6T310, Q8AVS6, Q8IYK8, Q8QFP8, Q8VEL9, Q8VHP8, Q8VHQ4, Q8WXH6

Diamond homologs: A1DZY4, A6QP66, A8NU18, C4YKT4, O08989, O14807, O35929, O88667, O93856, O94363, P01119, P03967, P08645, P08647, P0CY32, P10114, P10536, P11233, P11234, P15064, P17609, P22124, P22126, P22278, P22279, P22280, P28775, P32254, P36860, P36863, P48555, P59279, P61105, P61225, P61226, P61227, P62070, P62071, P63320, P63321

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

37 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	30
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

331 predictions. Top by Δscore:

Variant	Effect	Δscore
13:27271064:GAGCG:G	donor_gain	1.0000
13:27271066:GCG:G	donor_gain	1.0000
13:27271069:G:GG	donor_gain	1.0000
13:27271479:TTCAG:T	acceptor_loss	1.0000
13:27271480:TCA:T	acceptor_loss	1.0000
13:27271481:CA:C	acceptor_loss	1.0000
13:27271482:A:AG	acceptor_gain	1.0000
13:27271483:G:GT	acceptor_gain	1.0000
13:27271483:GC:G	acceptor_gain	1.0000
13:27271483:GCA:G	acceptor_gain	1.0000
13:27271483:GCAA:G	acceptor_gain	1.0000
13:27271483:GCAAT:G	acceptor_gain	1.0000
13:27271536:TACAG:T	donor_gain	1.0000
13:27271537:ACAG:A	donor_gain	1.0000
13:27271537:ACAGG:A	donor_loss	1.0000
13:27271538:CAG:C	donor_gain	1.0000
13:27271539:AG:A	donor_gain	1.0000
13:27271539:AGG:A	donor_loss	1.0000
13:27271540:GG:G	donor_gain	1.0000
13:27271541:G:GG	donor_gain	1.0000
13:27271541:GTGAG:G	donor_loss	1.0000
13:27271630:A:AG	acceptor_gain	1.0000
13:27271631:T:G	acceptor_gain	1.0000
13:27271635:CCA:C	acceptor_loss	1.0000
13:27271637:A:AG	acceptor_gain	1.0000
13:27271637:AG:A	acceptor_gain	1.0000
13:27271637:AGGCA:A	acceptor_loss	1.0000
13:27271638:G:GT	acceptor_gain	1.0000
13:27271638:GG:G	acceptor_gain	1.0000
13:27271638:GGC:G	acceptor_gain	1.0000

AlphaMissense

1570 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
13:27271513:T:C	F52L	1.000
13:27271515:C:A	F52L	1.000
13:27271515:C:G	F52L	1.000
13:27273209:G:C	K148N	1.000
13:27273209:G:T	K148N	1.000
13:27271060:G:T	G39V	0.999
13:27271496:G:C	R46P	0.999
13:27271514:T:C	F52S	0.999
13:27273105:T:C	S114P	0.999
13:27273123:A:C	S120R	0.999
13:27273125:C:A	S120R	0.999
13:27273125:C:G	S120R	0.999
13:27273217:T:C	L151P	0.999
13:27271059:G:C	G39R	0.998
13:27271060:G:A	G39D	0.998
13:27271502:T:C	L48P	0.998
13:27271505:C:T	T49I	0.998
13:27271514:T:G	F52C	0.998
13:27271698:G:C	D81H	0.998
13:27273106:C:T	S114F	0.998
13:27273202:G:A	G146D	0.998
13:27273214:A:C	D150A	0.998
13:27273214:A:G	D150G	0.998
13:27273229:G:C	R155P	0.998
13:27273295:C:T	S177F	0.998
13:27271044:G:C	G34R	0.997
13:27271059:G:T	G39C	0.997
13:27271063:A:T	K40M	0.997
13:27271064:G:C	K40N	0.997
13:27271064:G:T	K40N	0.997

dbSNP variants (sampled 300 via entrez): RS1000477741 (13:27270617 C>T), RS1000482418 (13:27274896 T>C), RS1001276397 (13:27274400 C>G,T), RS1002454162 (13:27270584 C>G), RS1002495274 (13:27274636 C>A), RS1002562419 (13:27275586 T>C), RS1003599606 (13:27271077 G>A,C,T), RS1003742312 (13:27270305 C>T), RS1004591678 (13:27269318 A>C), RS1004966535 (13:27273877 A>G), RS1005010171 (13:27269747 G>A), RS1005341271 (13:27275303 C>T), RS1005392166 (13:27275646 T>A), RS1005754573 (13:27274020 G>T), RS1005878329 (13:27269236 C>T)

Disease associations

OMIM: gene MIM:612403 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

47 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression, decreases methylation	3
Dexamethasone	increases expression, affects cotreatment	2
Tretinoin	increases expression, decreases expression	2
aristolochic acid I	increases expression	1
bisphenol F	affects cotreatment, increases expression	1
sotorasib	affects cotreatment, increases expression	1
methylmercuric chloride	increases expression	1
methyleugenol	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, increases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
sulforaphane	decreases expression	1
sodium arsenite	decreases expression	1
potassium chromate(VI)	affects cotreatment, increases expression	1
cupric chloride	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	decreases reaction, affects cotreatment, increases expression	1
epigallocatechin gallate	affects cotreatment, increases expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
perfluoro-n-nonanoic acid	decreases expression	1
perfluorohexanesulfonic acid	increases expression	1
licochalcone B	increases expression	1
trametinib	affects cotreatment, increases expression	1
NVP-BKM120	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Calcitriol	decreases expression, affects cotreatment	1
Cisplatin	increases expression	1
Dimethyl Sulfoxide	increases expression	1
Drugs, Chinese Herbal	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.